10-Q: Sangamo Therapeutics Reports Q1 2025 Financial Results and Provides Business Update

Sangamo Therapeutics announces its Q1 2025 financial results, highlighting progress in neurology programs and ongoing efforts to secure additional funding amid going concern uncertainties.

Summary

• Sangamo Therapeutics reported a net loss of $30.6 million for the three months ended March 31, 2025, compared to a net loss of $49.1 million for the same period in 2024.
• Revenues increased to $6.4 million, primarily driven by the Pfizer collaboration and Sigma-Aldrich license agreement.
• Research and development expenses decreased to $26.0 million due to lower personnel costs and program reprioritization.
• The company is focusing on neurology development, including epigenetic regulation therapies and novel AAV capsid delivery technology.
• Sangamo is preparing for a Phase 1/2 clinical study of ST-503 for intractable pain due to iSFN, expected to commence in mid-2025.
• A clinical trial authorization submission for ST-506, a treatment for prion disease, is expected in Q1 2026.
• The company is seeking a commercialization partner for its Fabry disease program and expects a pivotal read-out by the end of Q2 2025.
• Sangamo has entered into a global capsid delivery license agreement with Eli Lilly and Company for CNS diseases, receiving an $18.0 million upfront payment.
• The company acknowledges substantial doubt about its ability to continue as a going concern and is actively seeking additional funding.
• As of March 31, 2025, cash and cash equivalents totaled $25.2 million, expected to be sufficient only until early Q3 2025.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While there are positive developments in the pipeline and new collaborations, the going concern warning and financial constraints weigh heavily on the outlook.

Positives

• Revenues increased significantly in Q1 2025, driven by collaborations and licensing agreements.
• The company is making progress in its neurology pipeline, with clinical trials planned for ST-503 and ST-506.
• A new licensing agreement with Eli Lilly and Company provides an upfront payment and potential for future milestones.
• The company is actively seeking a commercialization partner for its Fabry disease program.
• The FDA has provided a clear CMC pathway to a planned BLA submission as early as the first quarter of 2026 for the Fabry disease program.

Negatives

• Sangamo reported a net loss of $30.6 million for Q1 2025.
• The company acknowledges substantial doubt about its ability to continue as a going concern.
• Cash and cash equivalents are expected to be sufficient only until early Q3 2025.
• The company is dependent on securing additional funding to continue operations and advance its programs.
• The Pfizer collaboration terminated in April 2025, impacting future revenue potential.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding.
• Failure to secure a commercialization partner for the Fabry disease program could impair the ability to raise additional capital.
• Clinical trials may not demonstrate safety and efficacy, preventing regulatory approval.
• The company may face challenges in manufacturing and process development.
• Macroeconomic conditions could negatively impact operations and the ability to raise capital.
• The company may not regain compliance with Nasdaq listing standards, potentially leading to delisting.
• International trade policies, including tariffs, sanctions and trade barriers may adversely affect the business.
• Disruptions at the FDA, including due to a reduction in workforce and/or inadequate funding, could prevent FDA from performing normal functions on which the business relies.

Future Outlook

The company expects to commence enrollment and dosing of patients in mid-2025 for the Phase 1/2 clinical study of ST-503, subject to securing adequate additional funding. Preliminary proof of efficacy data from the Phase 1/2 study is expected in the fourth quarter of 2026. A CTA submission for the prion program is expected in the first quarter of 2026, subject to securing adequate additional funding. The company plans to begin clinical trial enrollment and dosing in mid-2026, subject to securing adequate additional funding, with preliminary clinical data anticipated in the fourth quarter of 2026. A pivotal read-out for the Fabry disease program is expected by the end of the second quarter of 2025. A BLA submission is planned as early as the first quarter of 2026.

Management Comments

• Management believes that there is substantial doubt about the company's ability to continue as a going concern for a period of twelve months from the date these Condensed Consolidated Financial Statements are issued.
• Management's plans include pursuing one or more of the following steps to raise additional capital: raise funding through the sale of the Company's common stock, including sales under the at-the-market offering program with Jefferies LLC; raise funding through debt or royalty financing; and establish collaborations with potential partners to advance the Company's product pipeline.

Industry Context

Sangamo's focus on genomic medicine and neurology aligns with growing interest in gene therapy and gene editing for neurological disorders. The collaborations with major pharmaceutical companies like Lilly, Genentech, and Astellas highlight the value of Sangamo's technology platforms. However, the company's financial challenges reflect the high costs and risks associated with drug development in this sector.

Comparison to Industry Standards

• Sangamo's collaborations with major pharmaceutical companies like Lilly, Genentech, and Astellas are comparable to other gene therapy companies that partner with larger firms to advance their programs.
• The $18 million upfront payment from Lilly is within the range of upfront payments for similar licensing agreements in the gene therapy space.
• The potential for up to $1.4 billion in milestones from the Lilly agreement is significant but contingent on successful development and commercialization, which is typical in the industry.
• The company's focus on neurology and AAV capsid delivery technology is in line with industry trends, as these areas are attracting significant investment and attention.
• The company's financial challenges and going concern uncertainty are not uncommon for early-stage biotech companies, but highlight the need for successful clinical development and commercial partnerships.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and the risk of delisting from Nasdaq.
• Employees face uncertainty due to potential cost reduction measures and restructuring.
• Patients may benefit from the development of new therapies for neurological diseases.
• Collaborators and partners may be impacted by the company's financial challenges.

Next Steps

• Commence enrollment and dosing of patients in mid-2025 for the Phase 1/2 clinical study of ST-503.
• Submit a clinical trial authorization for ST-506 in Q1 2026.
• Seek a commercialization partner for the Fabry disease program.
• Execute BLA readiness activities for isaralgagene civaparvovec.
• Continue business development discussions for STAC-BBB.
• Regain compliance with Nasdaq listing standards.

Key Dates

Keywords

Sangamo, Therapeutics, Neurology, Genomic Medicine, STAC-BBB, Fabry Disease, Hemophilia A, Clinical Trials, Funding, Collaboration, Epigenetic Regulation, AAV Capsid, Financial Results, Going Concern